Recombinant Human FGF-8
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | FGF-8 (FGF-8b) is a heparin binding growth factor belonging to the FGF family. Proteins of this family play a central role during prenatal development and postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. There are 4 known alternate spliced forms of FGF8; FGF8A, FGF-8B, FGF-8E and FGF-8F. The human and murine FGF8 A and B are identical unlike human and M FGF8 E and F are 98% identical. FGF-8 targets mammary carcinoma cells and other cells expressing the FGF receptors. Recombinant human FGF-8 (FGF-8b) is a 22.5 kDa protein consisting of 194 amino acid residues. |
---|---|
BiologicalActivity | The ED50 as determined by the dose-dependent stimulation of thymidine uptake by BaF3 cells expressing FGF- receptors is ≤ 0.5 ng/ml, corresponding to a specific activity of ≥ 2 x 106 units/mg. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human FGF-8 is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.